CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. LOAN AND...Loan and Security Agreement • August 9th, 2023 • enGene Holdings Inc. • Biological products, (no disgnostic substances) • California
THIS LOAN AND SECURITY AGREEMENT is made and dated as of December 30, 2021 and is entered into by and between enGene Inc., a corporation organized under the laws of Canada, and enGene USA, Inc., a Delaware corporation, and each of their Subsidiaries (hereinafter collectively referred to as, jointly and severally, the “Borrower”), the several banks and other financial institutions or entities from time to time parties to this Agreement (collectively, referred to as the “Lenders”) and HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent, collateral agent and hypothecary representative for itself and the Lenders (in such capacities, the “Agent”).
LEASE AMENDMENT AGREEMENT dated effective October 1, 2022 (the “Amendment”)Lease Amendment Agreement • August 9th, 2023 • enGene Holdings Inc. • Biological products, (no disgnostic substances)
NOW, THEREFORE in consideration of the foregoing and the mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follow:
CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. LETTER AGREEMENTLetter Agreement • August 9th, 2023 • enGene Holdings Inc. • Biological products, (no disgnostic substances) • Quebec
THIS LETTER AGREEMENT (this “Agreement”) is made as of May 16, 2023 between ENGENE INC., (the “Corporation”), Investissement Quebec (“IQ”), Forbion European Acquisition Corp. (“FEAC”), and enGene Holdings Inc. (“Newco” and together with the Corporation, FEAC and IQ, the “Parties”).
LEASE AGREEMENTLease Agreement • August 9th, 2023 • enGene Holdings Inc. • Biological products, (no disgnostic substances) • Quebec
THIS LEASE AGREEMENT (this “Lease”) is made this 29 day of December, 2022, between ARE-CANADA NO. 5 HOLDINGS ULC, a British Columbia company (“Landlord”), and ENGENE INC., a corporation governed by the Canada Business Corporations Act (“Tenant”).
LEASE AGREEMENTLease Agreement • August 9th, 2023 • enGene Holdings Inc. • Biological products, (no disgnostic substances)
NOW THEREFORE, in consideration of the covenants, rights and obligations contained in this Agreement, the parties hereto agree as follows:
LEASE AMENDMENT AGREEMENT NO 2 dated effective April 1, 2023 (the “Amendment”)Lease Amendment Agreement • August 9th, 2023 • enGene Holdings Inc. • Biological products, (no disgnostic substances)
NOW, THEREFORE in consideration of the foregoing and the mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follow:
LEASE AMENDMENT AGREEMENT NO 3 dated effective September 1, 2023 (the “Amendment”)Lease Amendment Agreement • August 9th, 2023 • enGene Holdings Inc. • Biological products, (no disgnostic substances)
NOW, THEREFORE in consideration of the foregoing and the mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follow:
CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. MASTER...Master Service Agreement • August 9th, 2023 • enGene Holdings Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Agreement is made, effective as of the date executed by the last party to sign below (such date, the “Effective Date”), by and between BioAgilytix Labs, LLC, a Delaware Limited Liability Company, having a principal place of business at 2300 Englert Drive, Durham, NC 27713, together with its Affiliates and Subsidiaries (“collectively BioAgilytix”) and ENGENE INC., a Canadian corporation, having its principal place of business at 7171 Rue Frederick Banting, Saint-Laurent, Quebec H4S 1Z9, Canada (“ENGENE”).
